Literature DB >> 23282873

An evaluation of utility measurement in Crohn's disease.

J C Gregor1, J W McDonald, N Klar, R Wall, K Atkinson, B Lamba, B G Feagan.   

Abstract

SUMMARY: : We evaluated the use of utility measurements to assess the quality of life of patients with Crohn's disease. Utility scores were obtained using the Time Trade-Off (TTO), Standard Gamble, and Visual Analog Scale (VAS) methods in 180 consecutive patients with Crohn's disease. The mean utility scores of patients with a spectrum of disease severity were compared with other measures of disease activity to assess the operating properties of these instruments. All methods of utility estimation yielded lower mean scores in patients with more severe disease. (Remission versus chronically active, therapy resistant disease: TTO 0.96 versus 0.88; Standard Gamble 0.88 versus 0.74; VAS 0.84 versus 0.61). TTO scores were consistently higher than those derived by the other methods (p = 0.001). The utility scores were reliable in patients who were stable (intraclass correlation coefficient 0.55-0.84), but were less responsive than the Crohn's Disease Activity Index (responsiveness ratio 0.97-1.3 versus 2.10) to changes in disease severity. Patients with active Crohn's disease have decreased quality of life as measured by utility scores. Although utilities are valid and reliable quality of life assessments, they are less responsive than other measures of outcome used for clinical trials.

Entities:  

Year:  1997        PMID: 23282873

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  30 in total

1.  Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model.

Authors:  Corey A Siegel; Samuel R G Finlayson; Bruce E Sands; Anna N A Tosteson
Journal:  Clin Gastroenterol Hepatol       Date:  2011-10-01       Impact factor: 11.382

Review 2.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  QALYs: are they helpful to decision makers?

Authors:  Maurice McGregor; J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Health related quality of life in inflammatory bowel disease: the impact of surgical therapy.

Authors:  Konstantin Umanskiy; Alessandro Fichera
Journal:  World J Gastroenterol       Date:  2010-10-28       Impact factor: 5.742

5.  Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Authors:  Andrew P Yu; Scott Johnson; Si-Tien Wang; Pavel Atanasov; Jackson Tang; Eric Wu; Jingdong Chao; Parvez M Mulani
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Estimates of health utility scores in chronic kidney disease.

Authors:  Nigar Sekercioglu; Bryan Curtis; Sean Murphy; Gord Blackhouse; Brendan Barrett
Journal:  Int Urol Nephrol       Date:  2017-07-21       Impact factor: 2.370

7.  Funding a smoking cessation program for Crohn's disease: an economic evaluation.

Authors:  Stephanie Coward; Steven J Heitman; Fiona Clement; Maria Negron; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Cynthia Seow; Yvette P Y Leung; Gilaad G Kaplan
Journal:  Am J Gastroenterol       Date:  2014-10-28       Impact factor: 10.864

8.  Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease.

Authors:  Philip N Okafor; Francis A Farraye; Adetoro T Okafor; Daniel O Erim
Journal:  Dig Dis Sci       Date:  2015-07-16       Impact factor: 3.199

9.  Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.

Authors:  Heather Catt; Keith Bodger; Jamie J Kirkham; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

10.  The effects of thiopurine therapy on health-related quality of life in Inflammatory Bowel Disease patients.

Authors:  Guillermo Bastida; Pilar Nos; Mariam Aguas; Belén Beltrán; Marisa Iborra; Vicente Ortiz; Vicente Garrigues; Rafael Estevan; Julio Ponce
Journal:  BMC Gastroenterol       Date:  2010-03-02       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.